Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Factor VIII inhibitors

L W Hoyer1

  • 1American Red Cross, Rockville, Maryland, USA.

Current Opinion in Hematology
|September 1, 1995
PubMed
Summary
This summary is machine-generated.

Factor VIII inhibitors are serious complications for hemophilia A patients. Recent research improves understanding of inhibitor incidence, at-risk patients, antibody characterization, and therapies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

In hemophilia A and autoantibody inhibitor patients: the factor VIII A2 domain and light chain are most immunogenic.

Thrombosis research·2001
Same author

Characterization of the immune response to factor VIII using hemophilia A* mice.

Haematologica·2001
Same author

Mechanism of the immune response to human factor VIII in murine hemophilia A.

Thrombosis and haemostasis·2001
Same author

Role of CD154 in the secondary immune response: the reduction of pre-existing splenic germinal centers and anti-factor VIII inhibitor titer.

European journal of immunology·2000
Same author

Prevention and treatment of factor VIII inhibitors in murine hemophilia A.

Blood·2000
Same author

Inhibitor antibody development and T cell response to human factor VIII in murine hemophilia A.

Thrombosis and haemostasis·1999

Area of Science:

  • Hematology
  • Immunology

Background:

  • Factor VIII inhibitors, which neutralize Factor VIII's clotting function, are a major complication in hemophilia A treatment.
  • These antibodies can also arise spontaneously in healthy individuals, causing rare bleeding events.

Purpose of the Study:

  • To review recent advancements in understanding Factor VIII inhibitors.
  • To highlight progress in identifying at-risk populations and improving therapeutic strategies.

Main Methods:

  • This review synthesizes findings from recent studies on Factor VIII inhibitors.
  • Key areas explored include incidence, risk factors, antibody characteristics, and therapeutic developments.

Main Results:

  • New insights have been gained into the frequency of inhibitor development post-Factor VIII treatment.

Related Experiment Videos

  • Improved methods for identifying patients susceptible to inhibitor formation have emerged.
  • Characterization of anti-Factor VIII antibodies and novel therapeutic approaches are advancing.

    • Conclusions:

    • Recent research has significantly enhanced our comprehension of Factor VIII inhibitors.
    • These advancements pave the way for better prevention and treatment strategies for hemophilia A and acquired inhibitors.